Daily News for Neuros, Nurses & Savvy MSers: 208,152 Viewers, 8,368 Stories & Studies
Click Here For My Videos, Advice, Tips, Studies and Trials.
Timothy L. Vollmer, MD
Department of Neurology
University of Colorado Health Sciences Center Professor

Co-Director of the RMMSC at Anschutz Medical Center

Medical Director-Rocky Mountain MS Center
Click here to read my columns
Brian R. Apatoff, MD, PhD
Multiple Sclerosis Institute
Center for Neurological Disorders

Associate Professor Neurology and Neuroscience,

Weill Medical College of Cornell University

Clinical Attending in Neurology,
New York-Presbyterian Hospital
You'll get FREE Breaking News Alerts on new MS treatments as they are approved

HERE'S A FEW OF OUR 6000+ Facebook & MySpace FRIENDS
Timothy L. Vollmer M.D.
Department of Neurology
University of Colorado Health Sciences Center
Co-Director of the RMMSC at Anschutz Medical Center
Medical Director-Rocky Mountain MS Center

Click to view 1280 MS Walk photos!

"MS Can Not
Rob You of Joy"
"I'm an Mom has MS and we have a message for everyone."
- Jennifer Hartmark-Hill MD
Beverly Dean

"I've had MS for 2 years...this is the most important advice you'll ever hear."
"This is how I give myself a painless injection."
Heather Johnson

"A helpful tip for newly diagnosed MS patients."
"Important advice on choosing MS medication "
Joyce Moore

This page is powered by Blogger. Isn't yours?



Genzyme’s LEMTRADA Maintains Effectiveness in Reducing Brain Atrophy According to Recent Study Results

Genzyme presented new magnetic resonance imaging (MRI) data from the Lemtrada® (alemtuzumab) clinical development program on April 23, 2015, at the 67th American Academy of Neurology (AAN) Annual Meeting. The company showed that in the extension phase of two Phase III trials (years 3 and 4), the drug continued to protect the nervous system from damage. Through year four, drug side effects were the same as those observed during the first two years.

Phase III trials of Lemtrada consisted of two-year studies comparing Lemtrada with high-dose subcutaneous interferon beta-1a (Rebif®). The trials were called CARE-MS I and CARE-MS II (CARE stands for Comparison of Alemtuzumab and Rebif Efficacy in Multiple Sclerosis). In Phase III pivotal studies, Genzyme researchers studied people with relapsing remitting multiple sclerosis (RRMS) treated with Lemtrada. The investigators took magnetic resonance imaging (MRI) measurements to assess nervous system damage.

The scientists found that nervous system damage (brain atrophy) decreased over four years among Lemtrada patients in CARE-MS I. In the second trial, CARE-MS II, nervous system damage decreased over three years and was low in the fourth year. In year three and four, brain volume loss was less than during the first two-years for both studies. Treatment with Lemtrada in both studies decreased the risk of developing new lesions compared to interferon beta-1a. About 70% of participants had no new lesions in years 3 and 4 for both studies.
“It is very promising that most Lemtrada patients experienced slowing of brain atrophy and remained free of new lesions despite receiving their last treatment course three years previously,” said Dr. Alasdair Coles, Professor, Department of Clinical Neurosciences, University of Cambridge. “These new MRI data are consistent with the clinical data from the extension study that provide additional evidence of the sustained efficacy of Lemtrada on both relapses and disability.”

“The four-year MRI data support the prolonged efficacy of Lemtrada,” said Genzyme President and CEO, David Meeker, M.D. “These results are encouraging, as they provide further evidence of Lemtrada’s potential to change the treatment approach for people living with relapsing forms of MS.”

Most participants in the CARE-MS Phase III trials enrolled in the extension study — a total of 90% of all participants. They received additional Lemtrada in the extension study if they had at least one relapse or at a minimum of two new or enlarging brain or spinal cord lesions. 

The FDA approved Lemtrada in November of 2014, for relapsing forms of MS. In CARE-MS I, Lemtrada was more effective than interferon beta-1a at reducing relapse — a statistically significant effect. However, slowing of disability progression was not different in the two groups at a level that reached statistical significance. However, in CARE-MS II, Lemtrada was more effective than interferon beta-1a at reducing relapse, and disability was slowed down in people taking Lemtrada compared to those who took interferon beta-1a at a rate that reached statistical significance.

Story Source: The above story is based on materials provided by MULTIPLESCLEROSISNEWSTODAY
Note: Materials may be edited for content and length 
Click here to read original article


Go to Newer News Go to Older News